Latest News about NVS
Recent news which mentions NVS
3 No-Brainer Stocks to Buy for Under $100 Right Now
October 28, 2023
From Motley Fool
7 Undervalued Stocks to Buy Before Everyone Else
October 26, 2023
From InvestorPlace
US Stock Futures Surge Ahead Of Microsoft, Google Earnings: Analyst Says 'Magnificent Seven' Unlikely To See Tesla-Like Volatility After Results
October 24, 2023
From Benzinga
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
October 24, 2023
From Benzinga
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
October 23, 2023
From Benzinga
7 Healthcare Stocks to invest in for a Healthy Future
October 20, 2023
From InvestorPlace
2 Biotech Stocks That Could Make You Richer
October 17, 2023
From Motley Fool
3 Unstoppable Stocks to Buy and Hold for Decades
October 17, 2023
From Motley Fool
From MarketWatch
RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan
October 10, 2023
From Benzinga
From InvestorPlace
Protecting Cannabis Products & More: New Sustainable Child-Resistant Packaging By Dymapak
October 05, 2023
From Benzinga
From MarketWatch
Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
October 04, 2023
From Benzinga
Novartis Shares Decline As Spin Off Sandoz's Market Debut Falls Short of Expected Valuation
October 04, 2023
Tickers
NVS
From Benzinga
From InvestorPlace
Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares
October 04, 2023
From Benzinga
Cal-Maine Foods, A10 Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 04, 2023
From Benzinga
Novartis spinoff Sandoz valued at $11.2 billion in trading debut
October 04, 2023
Tickers
NVS
From MarketWatch
From Benzinga
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
October 03, 2023
From Benzinga
Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer
September 29, 2023
From Benzinga
Allakos' Antibodies For Chronic Skin Conditions, Analyst Sees Over 400% Stock Upside
September 27, 2023
From Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
From Benzinga
From Benzinga